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EXPAREL (bupivacaine extended-release liposome injection), DepoFoam bupivacaine, is in development for prolonged
postsurgical analgesia. Repeat-dose toxicity studies were conducted in rabbits and dogs to compare the potential local and
systemic toxicities of EXPAREL and bupivacaine HCl (Bsol), and the reversibility of any eﬀe c t s .D o g st o l e r a t e dm u c hl a r g e r
doses than rabbits. EXPAREL-related minimal-to-moderate granulomatous inﬂammation was noted at the injection sites. In
recovery animals, the granulomatous inﬂammation was observed less frequently and was characterized by an increased number
of multinucleated giant cells. These eﬀects were considered a normal response to liposomes and nonadverse. Rabbits are more
sensitivethandogs.Inrabbits,convulsionswerenotedwithEXPARELandmorefrequentlywithBsol;aNOAELwasnotidentiﬁed.
In dogs, EXPAREL was well tolerated (NOAEL>30mg/kg/dose). The cumulative exposure of EXPAREL in these studies is well in
excess of the proposed maximum single-dose exposure that is intended in humans.
1.Introduction
The investigational drug EXPAREL (DB, DepoFoam bupi-
vacaine; bupivacaine extended-release liposome injection)
is a multivesicular liposomal formulation of bupivacaine
being developed for postsurgical analgesia ([1], Angst
2006). Dierucoylphosphatidylcholine (DEPC), a phospho-
lipid excipient, is unique to the delivery system present
in EXPAREL and has not been previously included in
otherDepoFoam-basedapprovedproducts,thatis,DepoDur
(morphine sulfate) and DepoCyt (cytarabine).
Since the association of bupivacaine to multivesicular
liposomes delays the vascular absorption of bupivacaine
released from the lipid vesicles, DepoFoam bupivacaine may
prevent accumulation of unexpectedly high (possibly toxic)
blood and/or tissue concentrations of bupivacaine compared
to bupivacaine HCl (Bsol) and therefore may provide a safer
alternative to current therapies.
Systemic reactions to bupivacaine mainly involve the
central nervous (CNS) and/or cardiovascular (CV) systems
[2]. These eﬀects have been described in the literature in
several species including humans [3–8]. (Since these eﬀects
have been extensively summarized in the literature, only a
selection of relevant references is given here (please refer to
the Discussion section for further detail).)
W h e ng i v e ni ns u ﬃciently large doses, liposomal formu-
lationsmaybeirritatingtosubcutaneous(sc)tissues,causing
nonspeciﬁc local reactions. Particularly during repeated
exposure, the presence of exogenous lipid materials in the
sc space may serve as a nidus for the development of a
foreignbody type reaction in surrounding tissues. Therefore,
it seems possible that prolonged, repeated exposure to2 Journal of Drug Delivery
EXPAREL could intensify the degree of sensitivity to bupi-
vacaine and/or DepoFoam particles particularly in rabbits,
because of the thinness of the skin layer and relative absence
of sc fat.
As part of the nonclinical development program, the
safety of repeat-dose administration of EXPAREL compared
toBsolwasevaluatedintwospeciesinaccordancewithInter-
national Conference on Harmonization (ICH) guidelines.
These multiple-dose studies in rabbits and dogs (non-
surgical model) were designed to complement single-dose
toxicology testing (surgical hernia repair model) in the same
species, in which animals were exposed to the same amount
of drug.
Groups of animals were given EXPAREL at a dose level
of 9mg/kg, 18mg/kg, or 30mg/kg in comparison with Bsol
9mg/kg (7.5mg/mL), or saline via sc twice weekly injection.
These studies included evaluation of both local eﬀects as well
as the usual broad range of systemic eﬀects.
It was possible to meaningfully compare the toxicology
ﬁndings and concurrent systemic exposure in rabbits and
dogs since the same protocol in a whole-body system, assay
methodology, and data acquisition systems were used. The
clinical relevance of the toxicology results was evaluated in
relation to the intended clinical use of EXPAREL (single
dose) in patients.
2.MaterialsandMethods
2.1. Materials
2.1.1. Description of DepoFoamTM Technology. The Depo-
Foam drug delivery system is a proprietary, injectable
technology that provides a sustained release of therapeutic
compounds. The DepoFoam system consists of microscopic,
polyhedral, lipid-based particles composed of numerous
nonconcentric, aqueous chambers containing the drug in
solution. Each chamber in this multivesicular liposome is
separated from adjacent chambers by lipid membranes [9,
10].
The DepoFoam particle components are naturally occur-
ring or synthetic analogues of common lipids, including
phospholipids, cholesterol, and triglycerides.
2.1.2. Test Article. EXPAREL (DepoBupivacaine, DB; bupi-
vacaine extended-release liposome injection using multiv-
esicular DepoFoam technology), 15mg/mL and 25mg/mL
(expressed as anhydrous bupivacaine base), was provided by
Pacira Pharmaceuticals, Inc., San Diego, Calif. In the higher-
concentration EXPAREL system (25mg/mL), the multi-
vesicular liposome particle concentrations were increased
from approximately 35–40% of the total suspension volume,
to approximately 60–70% total suspension volume. (This
provided maximum local concentrations at the injection
site.)
2.1.3. Reference Product. Sensorcaine-MPF (methyl paraben
free; bupivacaine HCl injection, USP, Bsol 0.75%) was
supplied by AstraZeneca, Wilmington, Del.
2.1.4.ControlArticle. Saline(0.9%sodiumchlorideinjection
USP) was supplied by Abbott Laboratories, North Chicago,
Ill.
2.1.5. Animals. New Zealand White rabbits and Beagle dogs
were supplied by Covance Research Products, Kalamazoo,
Michigan, and Marshall BioResources, North Rose, NY,
respectively. The animals were 5–8 months (rabbit) and 4
months (dog) of age on arrival. The animals were acclimated
for a period of at least one week. The animals received
LabDiet (Certiﬁed Rabbit Diet no. 05007 and Certiﬁed
Dog Diet no. 05322; PMI Nutrition international, Inc.,
Richmond, Ind).
2.2. Methods
2.2.1. Study Protocol. All protocols were reviewed and
approved by the Institutional Animal Care and Use Com-
mittee (IACUC) of MPI Research, Inc., Auxvasse, Mo, for
compliance with regulations prior to study initiation. These
studies were conducted according to ICH guidelines and in
accordance with Good Laboratory Practices principles as set
forth by the United States Food and Drug Administration
(FDA), 21 CFR Part 58.
The repeat-dose studies were designed to use the fewest
number of animals possible, consistent with the objective of
the studies, with particular consideration to eliminating the
impact of surgical intervention on the normal behavior or
pattern of study animals.
2.2.2. Rationale for Dose Regimen. Groups of animals (N =
3/sex/group) were given EXPAREL at 9, 18, or 30mg/kg/dose
of a more highly concentrated formulation (bupivacaine
25mg/mL, with the proportional increase in lipid concen-
trations), Bsol 9mg/kg/dose (7.5mg/mL), or saline via sc
twice weekly injection. Each dose was administered by bolus
injection.
The protocols were designed to assess any exaggerated
pharmacological response and potential local and systemic
toxicities by selecting dose levels and concentrations at
multiples higher than the intended therapeutic dose. The sc
injection route administration was considered appropriate
as an alternate route of delivery to simulate the wound
inﬁltration route in the clinic.
T h ed o s el e v e l sa n dv o l u m e sw e r es e l e c t e do nt h eb a s i so f
available data from proprietary single-dose studies in rabbits
and dogs (hernia repair model), maximum projected clinical
dose, and published literature discussed here.
T h es e l e c t i o no ft h eh i g h e s td o s ei sb a s e do na n
EXPAREL dose of 30mg/kg given up to the limits of
solubility (25mg/mL). For the 30mg/kg dose, the injection
volume of 1.2mL/kg was calculated based on the supplied
concentration of 25mg/mL. It should be noted that the
studieswerenotdesignedtostudyspeciﬁcallyvolumeeﬀects.
G r e a t e rv o l u m eo fm o r ec o n c e n t r a t e dd r u gw a sn e c e s s a r yt o
achieve the highest dose level of EXPAREL 30mg/kg. Smaller
volumes or more dilute suspension of bupivacaine were used
at lower EXPAREL dose levels.Journal of Drug Delivery 3
Both the highest volume delivered (1.2mL/kg) and the
highest dose administered (9mg/kg) of bupivacaine HCl
were evaluated.
The 9mg/kg dose was based upon the published intr-
avenous (iv) lethality of 5–11mg/kg for bupivacaine [11],
and the lethality seen in a previous study in rabbits con-
ducted in the same laboratory (data not shown). Based on
these results, the maximum total nonlethal bupivacaine dose
was∼9mg/kgor1.2mL/kgofbupivacaineHCl(7.5mg/mL).
2.2.3. Rationale for Dose Frequency. The dose sites were
alternated between two scapular regions so that the studies
could be performed without the potential concern of injec-
tion site irritation obscuring or otherwise compromising the
ability to discern systemic eﬀects resulting from treatment-
related observations. Speciﬁcally, the twice weekly doses
were rotated at two diﬀerent sites to the right of the dorsal
midline (site 1) and to the left of the dorsal midline (site
2). The borders of the sites on opposite sides of the midline
had at least two inches to ensure that there was no cross
contamination between the sites. The dose was administered
on Days 1, 8, 15, and 22 (site 1) and on Days 4, 11, 18, and 25
(site 2). An individual site was dosed once every 3 days.
The study design takes into consideration the slow
egress of the lipid components from the injection sites as
previously shown in research studies (data not shown).
The repeat dose administration studies with EXPAREL were
designed with an intermittent dosing schedule to allow
enough time for dose egress from the injection sites between
each dose administration and minimize the risk of plasma
drug accumulation while providing suﬃcient exposure. The
twice weekly dosing schedule (Days 1, 4, 8, 11, 15, 18, 22,
and 25) was selected based on computer-based simulations
using WinNonlin (assuming linear kinetics) which suggested
continuous exposure of bupivacaine with no or minimal
accumulation over the course of the study. The simulated
proﬁle was derived from actual single dose data (high dose
only) and extrapolated to twice weekly administration (data
not shown).
Following 25 days of administration, three anima-
ls/sex/group were maintained for a 4-week treatment-free
recovery period. At the end of the dosing (Day 25) and
r e c o v e r yp e r i o d( D a y5 0 ) ,a n i m a l sw e r es a c r i ﬁ c e d( N =
3/sex/group/period).
2.2.4. Endpoints. Endpoints included clinical signs, clinical
pathology, electrocardiographic recording (EKG, dog only),
organ weight, full histopathologic tissue evaluation, and
toxicokinetics on Day 1 (ﬁrst dose) and Day 25 (last day of
dosing) (through 72 hours postdose). EKG was performed
prior to dosing and during the last week of dosing (Day 22)
and the last week of the recovery period (Day 50).
Any observable involuntary movements were noted.
Special attention was paid to signs of CNS disturbances and
seizures (i.e., tonic/clinic convulsions, tremors)
Microscopic examination of ﬁxed hematoxylin and
eosin-stained paraﬃn sections was performed on the sites
of injection and other protocol-speciﬁed tissues. A four-
step grading system was used to deﬁne gradable lesions
for comparison between dose groups (i.e., minimal, mild,
moderate, and severe).
2.2.5. Pharmacokinetic Assessment. Toxicokinetic samples
were collected from the 3 animals/sex/group designated for
a 4-week recovery period. Blood samples were taken from
the jugular veins in these groups on Day 1 and on Day 25,
at 0 (predose), and at 0.5, 1, 2, 4, 8, 12, 24, 48, and 72
hours after dosing. Samples were placed in tubes containing
K3 EDTA and stored on an ice block until centrifuged.
Each sample was 0.5–1mL. The test animals were not fasted
before blood collection unless collection times coincide with
clinical pathology collections. The plasma samples were
stored frozen at approximately −70◦C until analyzed.
Plasma concentrations of bupivacaine were measured
by MPI Analytical, Mattawan, Mich, using a validated LC-
MS/MS method. The assay is selective for the quantiﬁcation
of bupivacaine in rabbit and dog K3EDTA plasma in the
concentrations ranging from 10.0 to 10,000ng/mL. The PK
parameters were evaluated by a noncompartmental model
using WinNonlin, version 5.0 (Pharsight Corp., Mountain
View, Calif). The PK parameters were maximum plasma
concentration (Cmax), time at which the Cmax occurred
(tmax), and area under the plasma concentration, time data
(AUC0−t). The half-life (t1/2) was calculated in the late phase
of plasma concentration versus time curve.
3. Results and Discussion
3.1. Toxicology Results in Rabbits. There were no test article-
related eﬀects on body weight, food consumption, hema-
tology, coagulation, clinical chemistries, urinalysis, or organ
weight endpoints.
One female died on Day 19 one day after receiving the
sixth dose of EXPAREL (30mg/kg). In the last scheduled
observations, the animal was normal. Microscopically, no
cause of death was determined. In addition to the changes
seen at the injection sites in all the EXPAREL groups
(i.e., moderate swelling/thickening of the injection site),
this animal presented with microscopic ﬁndings consisting
of splenic, lymph node, and thymic lymphoid depletion.
This stress-associated lymphoid depletion is a common
ﬁnding in animals that die on study and is associated with
physiological stress. Additionally, a small amount of material
consistent with food matter was seen in the lungs, due most
likely to perimortem aspiration as there was no associated
inﬂammation. It should be noted that as a result, since this
rabbit was normally part of the recovery group, there were
only two of the three females surviving though the recovery
period.
When comparing with the same dose of EXPAREL, Bsol
(9mg/kg) was associated with a more frequent incidence
of tremors/convulsions (3/3 males and 1/3 female after the
third dose and 1/3 male after the ﬁfth dose) (Table 1). While
convulsions were not seen at the 30mg/kg dose of EXPAREL,
the convulsions seen with EXPAREL at the 9mg/kg (1/3
male after the ﬁrst dose) and 18mg/kg (1/3 female and 1/3
male after the fourth and ﬁfth dose) were considered to be4 Journal of Drug Delivery
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(b) Bupivacaine HCl solution (4x)
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(c) DepoFoam bupivacaine (EXPAREL, 20x)
Figure 1: Injection Site Findings in Rabbits on Day 26. (a): Saline Control. H&E 4x, (b): Bupivacaine HCl Solution, 9mg/kg. H&E
4x, (c): DepoFoam Bupivacaine 30mg/kg H&E 20x. Annotations are as follows: Black arrows: vacuolated macrophages, White arrows:
neovascularization, black asterisks: inﬂammation (chronic-active to chronic), white asterisks: mineralization.
bupivacaine-related because of the convulsions seen in the
Bsol dose group.
Macroscopically (Day 26), increased incidence of mild-
to-moderate red discoloration and swelling/thickening of
both of the injection sites was noted in animals of both sexes
at the 30mg/kg dose of EXPAREL. Red discoloration and
swelling/thickening were also noted at a low incidence in the
9 and 18mg/kg dose groups, but these local reactions were
comparable to Bsol or control saline group.
In recovery animals, mild red discoloration was seen
at a low incidence in all three EXPAREL-dosed males at
all the dose levels and in 1/3 female receiving EXPAREL
30mg/kg. These changes were, for the most part, correlated
with the microscopic ﬁndings of hemorrhage (HEM) and
neovascularization (NV) outlined below.
Test article-related microscopic ﬁndings (H&E staining)
were seen in both the sc injection sites, at all dose levels of
EXPAREL in the majority of animals after repeated dosing.
Microscopic ﬁndings consisted primarily of HEM, NV,
vacuolated (foamy) macrophages (VMs), and inﬂammation
(chronic-active or subacute). There was no consistent dose-
dependent response seen, except in increased numbers
of VMs at higher dose levels. This ﬁnding consisted of
individual VMs with ﬁnely vacuolated, foamy cytoplasm
forming aggregates, and/or extending along fascial planes,
with rare small numbers of lymphocytes and/or plasma cells
and no signiﬁcant numbers of multinucleated giant cells
(GCs). All ﬁndings were minimal-to-mild/moderate. None
of the changes above were seen in either saline or Bsol group
(Figure 1).
Injection site lesions resolved to some degree at recovery,
although minimal to mild HEM, VMs, NV, and inﬂamma-
tion were all present in low numbers in recovery animal. The
presence of VMs appeared to resolve in a dose-dependent
manner with none seen in males at the 9mg/kg dose or in
females at the 9 or 18mg/kg dose of EXPAREL.
3.2. Toxicology Results in Dogs. There were no test article-
related eﬀects on clinical observations, body weight, food
consumption, hematology, coagulation, clinical chemistries,
urinalysis, or organ weight endpoints. There were no EKG
abnormalities caused by EXPAREL, Bsol, or saline.
When compared to Bsol or saline control group, the only
notable ﬁndings were EXPAREL-related macroscopic and
microscopic observations in the injection sites of both male
and females (Days 26 and 54).Journal of Drug Delivery 5
Table 1: Incidence of convulsions following twice weekly subcutaneous injection of saline, EXPAREL 9, 18, and 30mg/kg, and bupivacaine
HCl solution 9mg/kg to rabbits (3/sex/group).
Treatment Dose (mg/kg)
Incidence of convulsions (clonic, unless noted)a
Week 1 Week 2 Week 3 Week 4
Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 Dose 7 Dose8
Bupivacaine HClb 9 — — 3(M,) 1(F) — 1(M)
(tremors) ———
EXPAREL
9 1(M)
(tonic) — — — — ———
18 — — — 1(F) (tremors) 1(M)
(tremors) ———
3 0 — — — — — ———
Saline 0 — — — — — — — —
aNumber of animal aﬀected on each dosing day; bSensorcaine M: male F: female; “—” No seizures recorded; cDose 1, 2, 3, 4, 5, 6, 7, 8 administered on Day 1,
4, 8, 11, 15, 18, 22, respectively.
Notes: On Day 1, one male rabbit receiving EXPAREL 9mg/kg had seizures intermittently lasting for about 10 minutes. Tonic movements were characterized
by prolonged and sustained convulsions started around 15 minutes postdose. On day 8, four animals receiving bupivacaine HCl solution (9mg/kg) (3(M)and
1(F)) had convulsions intermittently for 20 minutes. Clonic movements were characterized by rapid succession of spasms and relaxation. The convulsions
started around 15 minutes postdose and were less frequent with shorter duration as time went on. These animals recovered by 1 hour postdose. On Day 11,
1(F)receivingbupivacaineHClsolution18mg/kghadclonicconvulsions/tremorsintermittentlyfor5minutes.Thisanimalrecoveredby40minutespostdose.
On Day 15, 1(M) Bsol 9mg/kg and 1(M) EXPAREL 18mg/kg had clonic convulsions/tremors.
Swollen or thickened injection sites were noted in a
low number of terminal and recovery animals. Often, there
was no microscopic correlate to the red discoloration at
the injection sites. In rare occasions, the red discoloration
corresponded with HEM, edema, and/or sc subacute inﬂam-
mation. This macroscopic ﬁnding was considered to be a
result of physical trauma from the injection procedure and
not associated with treatment.
On both Day 26 and Day 54, minimal-to-moderate Gi
wasobservedinthesctissueofmaleandfemaledogs.Similar
microscopic ﬁndings were not observed in Bsol or saline
control group (Figure 2).
On Day 26, Gi was characterized by numerous VMs
and fewer lymphocytes, plasma cells, and/or GCs formed by
fused Macs with abundant cytoplasm and nuclei scattered
irregularly throughout the cytoplasm. The Gi was commonly
associated with edema and/or mineralization. The mineral
deposits were commonly surrounded by GCs. On Day 54,
G iw a so b s e r v e dl e s sf r e q u e n t l ya n dw a sc h a r a c t e r i z e db ya n
increased number of GCs sometimes associated with min-
eralization, but not edema. In one male receiving EXPAREL
9mg/kg, minimal edema not associated with inﬂammation
was noted.
In the EXPAREL groups, minimal-to-mild signs of hem-
orrhage, acute inﬂammation, erosion, epidermal exudates,
and/or subacute inﬂammation were observed sporadically at
the injection site of some terminal and recovery animals. The
subacute inﬂammation was primarily associated with hair
follicles and rarely surrounded intralesional mites consistent
with Demodex canis. These ﬁndings were considered proce-
dural.
3.3. Pharmacokinetic Results. The pharmacokinetic results
areshowninTables2–4.Speciesdiﬀerencewasobservedwith
lower Cmax (↓ 4 fold) and AUC (↓ 5 fold) for all dose levels
for EXPAREL (rabbit versus dog). The same observation was
made for Bsol with lower Cmax (↓ 4-9 fold) and AUC (↓ 4
fold).
Systemic exposure in female rabbits on Day 25 tended to
be larger than that in males (data not shown). In dogs, there
was not marked or consistent gender diﬀerence with regard
to the PK parameters for bupivacaine.
The PK results indicate that rabbits and dogs were
exposed to bupivacaine in a dose-related (although not
strictly dose-proportional) manner after twice weekly
repeated dosing of EXPAREL, at doses ranging from 9 to
30mg/kg. The degree of accumulation for EXPAREL upon
repeat dosing was no greater than two- to threefold which
indicate minimal-to-moderate carryover from the previous
dose (Tables 2 and 3).
In both species, the kinetic release proﬁle was consistent
with sustained release of the drug from the delivery system at
the site of administration (Figures 3,a n d4). The attenuation
of Cmax was on the order of two- to threefold compared to
Bsol after the ﬁrst dose. The accumulation was more evident
at the 30mg/kg dose in rabbits compared to dogs.
4. Discussion
When interpreting toxicology results, consideration has to
be given to the particular sensitivity of the species to local
reactions. The rabbit is, as a general rule, more sensitive
than other species to the action of most substances [12].
The sensitivity of the rabbit is due to the thinness of
the skin layer and the relative absence of sc fat [13]. It
is not surprising therefore that a series of twice weekly
injections of EXPAREL in which each exposure would
progressively intensify the degree of sensitivity may cause
local irritation from prolonged tissue exposure. After several
repeat injections, the compartments are nearly saturated and6 Journal of Drug Delivery
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(a) Saline (2x)
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(b) Bupivacaine HCl solution (2x)
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∗
(c) DepoFoam bupivacaine (EXPAREL, 4x)
Figure 2: Injection site ﬁndings in dogs on day 54. (a): Saline control. H&E 2x, (b): bupivacaine HCl solution, 9mg/kg. H&E
2x, (c): DepoFoam Bupivacaine 30mg/kg H&E 4x. Annotations are as follows: black arrows: vacuolated macrophages, white arrows:
neovascularization, black asterisks: inﬂammation (chronic-active to chronic), white asterisks: mineralization
Table 2: Accumulation ratios for EXPAREL and bupivacaine HCl solution (Day 25 versus Day 1) (mean ± SD; N = 3/sex/group).
(a) Rabbit
Treatment Bupivacaine
(mg/kg/dose)
Accumulation ratio (Day 25 versus Day 1)
AUC0–72hr(ng·hr/mL) Cmax(ng/mL) t1/2(hr) tmax(hr)
Bupivacaine HCl 9 0.88 1.02 1.17 1.07
EXPAREL
9 0.94 2.30 0.35 0.41
18 1.55 2.36 0.36 1.40
30 2.14 3.09 1.42 0.29
(b) Dog
Treatment Bupivacaine
(mg/kg/dose)
Accumulation ratio (Day 25 versus Day 1)
AUC0–72hr(ng·hr/mL) Cmax(ng/mL) t1/2(hr) tmax(hr)
Bupivacaine HCl 9 0.94 1.40 0.60 1.0
EXPAREL
9 1.90 2.46 0.61 1.0
18 1.90 2.34 0.25 1.5
30 1.71 1.44 1.38 0.26Journal of Drug Delivery 7
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Figure 3: Mean plasma concentrations of bupivacaine following
subcutaneous injection of DepoFoam bupivacaine (SKY0402, aka
EXPAREL) and bupivacaine HCl solution in rabbits (values repre-
sent mean ± SD, N = 3/sex/group). SKY0402: previous designation
for DB (aka EXPAREL).
therefore may no longer protect against potentially toxic
concentrations.
Also,whenassessingthepotentialexistenceofcumulative
systemic eﬀects of bupivacaine, the resulting plasma kinet-
ics is an important safety consideration because systemic
absorption of bupivacaine causing rapid high peaks are
associated with a more pronounced risk of CNS and CV
eﬀects. A brief review of the literature is provided below.
The toxic response of bupivacaine is characterized by a
complex interaction between the CNS and CV systems.
The response, at least in part, depends on how fast
the drug is administered, and the resultant blood/tissue
concentrations in target tissues are aﬀected. Particularly,
injection of repeated doses of local anesthetics may cause
signiﬁcant increases in plasma levels with each repeated dose
due to slow accumulation of the drug or its metabolites or
to slow metabolic degradation. It is diﬃcult to determine
the relationship between plasma levels and toxicity when
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Figure 4: Mean plasma concentrations of bupivacaine following
subcutaneousadministrationofDepoFoambupivacaine(SKY0402,
aka EXPAREL) and bupivacaine HCl solution in dogs (values
represent mean ± SD, N = 3/sex/group). SKY0402: previous
designation for DB (aka EXPAREL).
thesummatedresponseoriginatesfromtissueswithdiﬀerent
sensitivities, for example, cardiac muscles, neural tissues.
In animals (and humans), adverse eﬀects associated
with bupivacaine are generally dose-related and most often
are due to acutely high plasma levels resulting from rapid
absorptionofbupivacaineattheintendedsiteofaction,over-
dosage (i.e., enhanced absorption), diminished tolerance, or
unintentional intravascular injection [12, 14, 15].
In humans, dose-limiting eﬀects generally occur more
frequently with bupivacaine doses in the higher ranges.
Plasma concentrations of bupivacaine ranging from 3 to
5µg/mL produce a progression of CNS symptoms, including
headache and numbness; with increased plasma concentra-
tions, convulsions may occur [7, 16]. In most cases, life-
threatening acute toxicity aﬀecting the CNS and/or CV
system is not seen until there are suﬃciently elevated blood
levels. Bupivacaine can cause severe hypotension, respiratory
distress, CV collapse, and cardiac arrythmias including8 Journal of Drug Delivery
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ventricular ﬁbrillation which have been responsible for
fatalities [17, 18]. Large doses reaching the CNS system can
cause brain-stem depression resulting in severe respiratory
depression of apnea. In severe cases, cardiac arrest may
occur.
Cardiotoxicity is less easy to study in man, as the clinical
signs are not usually seen until the CNS toxicity is marked.
H o w e v e r ,C Vc o l l a p s ea n de v e nd e a t hc a no c c u rf r o m
low dose of bupivacaine without signiﬁcant CNS toxicity,
possibly as a result of the sudden onset of ventricular
ﬁbrillation [19, 20]. During ventricular ﬁbrillation and/or
hemodynamic instability, bupivacaine may produce severe
myocardial tissue hypoxia and acidosis contributing to the
overt toxic reactions [21–23]. Bupivacaine causes diﬀerential
eﬀects on the peripheral vascular resistance, with both
vasodilation and vasoconstriction having been reported [24–
28]. In addition, factors inﬂuencing plasma protein binding
(e.g., surgical stress, acid-base status of the patient, systemic
diseases which alter protein production, or competition
with other drugs for protein binding sites, as well as ﬂow
dynamics) may diminish individual tolerance).
Acute toxicity of bupivacaine has been reported in mice,
rats, rabbits, dogs, pigs, sheep, and monkeys. Endpoints
studied includes CNS (convulsions) and CVS toxicity (most
commonly, ventricular arrhythmias and circulatory col-
lapse),muscledegenerationandregeneration(particularlyin
rats), and maternal and fetal toxicity during delivery (mostly
in sheep) [29–38].
Neurotoxicity manifesting as convulsions is a well-
recognized complication of the administration of bupiva-
caine (and structural analogs) in both animals and humans.
CNStoxicityischaracterizedbyatwo-stagepathophysiologic
process. Shivering, muscle twitching, and tremors precede
tonic-clonic seizure activity as increased plasma levels of
bupivacaine preferentially block inhibitory central pathways,
leaving excitatory neurons unopposed.
Convulsions may occur due to absolute overdose, inad-
vertent iv injection or because of accidental early tourniquet
release in iv regional anesthesia [39]. The seizure is typically
of short duration and self-limiting. Respiratory arrest is
common because of the lack of muscle control associated
with the seizure. Progression to hypoxia, cyanosis, and
cardiac arrest may be rapid because of the consequences
of increased oxygen consumption of the tonic muscles and
respiratoryarrest[40].Physiologicalchangessuchasacidosis
and decrease of carbon dioxide tension may aﬀect the CNS
toxicity of local anesthetics [41].
There are a number of limitations to some published
in vivo studies since they were performed in anesthetized
animals with the complicating eﬀects of anesthesia and
surgery, and bupivacaine was administered at toxic doses
which did not allow to evaluate the absolute CNS and/or CV
eﬀects.Althoughthereisnogenerallyagreedstandardmodel
of toxicity, whole-system models are generally considered
more clinically relevant than others. However, the data
acquired are complicated by PK/PD interactions at diﬀerent
organ system, progressive (gradual) response, and intrinsic
control mechanisms. As a result, the dose response may be
discontinued and nonlinear [38].
CNSeﬀectsaregenerallyassumedtoprecedeCVtoxicity;
this notion was primarily derived from studies over the past
several decades comparing doses causing disappearance of
pulsative blood pressure and onset of convulsions eﬀects in
sheep [38]. This ratio was proposed as comparative measure
of CV toxicity. It was suggested that the higher the ratio,
the better the safety margin for a given compound. That
is, the wider the safety margin between convulsions and
CV collapse, the more time there may be for treatment
intervention when early signs of toxicity arise.
In a recent published report, the utility of site-directed
deliverysystemstodiﬀerentiatebetweenCNSandCVsystem
eﬀects has been emphasized [38]. The author questioned the
“CNS hypothesis” of cardiotoxicity and commented that it
may not be correct or, if it is, it may apply only to massive iv
overdose and not be sensitive towards the CNS site-selective
doses used in close arterial models. In a CNS site-directed
carotid arterial infusion studies, bupivacaine was found to be
more potent toward direct CNS toxicity and indirect cardiac
toxicity than levobupivacaine and ropivacaine; however,
there was no remarkable diﬀerence between the agents in
nonfatal arrhythmogenicity nor did it ﬁnd fatal arrhythmias
[35]. In site-directed coronary arterial infusion studies,
direct cardiac eﬀects of bupivacaine, levobupivacaine, and
ropivacaine were reported in the sheep [33]. In such model,
the time-course of myocardial depression was similar for
bupivacaine, levobupivacaine, and ropivacaine in doses that
cause no CVS eﬀects in conscious sheep. All these drugs
caused abrupt onset fatal dysrhythmias.
In rabbits, the mean convulsive doses (3.6mg/kg,
0.18mg/kg/min) and mean lethal doses of bupivacaine
(7.6mg/kg, ∼0.38mg/kg/min) were determined after slow iv
infusion of 0.32mL/min for 20 minutes, or until the animals
died. The clinical signs were salivation, tonic and clonic
convulsions, and respiratory arrest. After eight injections
of bupivacaine given sc at 30-minute intervals, a dose
of 6mg/kg produced convulsions in 2/5 rabbits while no
eﬀects were seen at 5mg/kg [14]. Metabolic consequences of
seizures include acidosis, hypoxia, and hyperkalemia.
In addition, cardiac toxicity is a well-recognized compli-
cation of the administration of bupivacaine (and structural
analogs) in both animals and humans [42–49]. Electrop-
hysiological and hemodynamic disturbances, including con-
duction blocks, ventricular arrhythmias, and fatal CV
c o l l a p s e ,h a v eb e e nr e p o r t e di np a t i e n t sa n do b s e r v e d
experimentally in animal models. However, it is unclear
whether the mechanism of death from bupivacaine toxicity
is primarily a consequence of cardiac arrhythmias or of
myocardial contractile depression, or some combination of
the two. Some groups suggest that cardiotoxic bupivacaine
concentrations produce a direct myocardial depression that
precedes the onset of lethal arrhythmias. Others proposed
that death from bupivacaine toxicity results from ventricular
tachyarrhythmias, or severe bradycardia, with or without
electromechanical dissociation, ultimately leading to CV
collapse.
Rabbits have been reported to be more sensitive to the
cardiotoxicity of bupivacaine than other animals [23]. It
seems possible that a more rapid heart rate and reducedJournal of Drug Delivery 11
cardiac output may predispose to tissue accumulation of
bupivacaine in the myocardium. In addition, tissue binding
aﬃnity (myocardium) and diﬀering rate of metabolism play
an important role.
4.1. Data Interpretation
4.1.1. Lack of Dose Response. In our studies, dogs toler-
ated much larger doses of EXPAREL than rabbits. A no-
observable-adverse-eﬀect level (NOAEL) dose for EXPAREL
or Bsol was not achieved in rabbits. The tonic and/or clonic
seizure activity seen with EXPAREL at 9 and 18mg/kg as well
with Bsol, although at lower frequency, were associated with
bupivacaine and not the liposomal formulation. Complete
recovery was observed after each dose indicating that these
eﬀects were reversible.
It is our opinion that the major factors involved in the
dramatic results seen in the rabbit compared to the dog
were its susceptibility to bupivacaine. Under these stringent
conditions, the test system was overwhelmed, which pre-
sumably contributed to the adverse eﬀects. The exaggerated
response achieved in rabbits was somewhat expected based
on literature review, and, in some respect, mimics adverse
reactionsthatcouldoccurasaresultofintravascularinfusion
and/or acute overdosing of bupivacaine.
It is unclear why no convulsions were seen at the higher
dose level of EXPAREL 30mg/kg. Apparently, there is a
toxicity threshold for concentration and exposure time, such
that when surpassed, irreparable damage to target organs is
produced. The lack of a clear dose response may reﬂect a
diﬀerential expression of potassium channels, and, perhaps,
compensatory mechanism(s) involving diﬀerential blockade
and/or stimulation of excitory/inhibitory pathways, which
could lead to a disproportional and nonlinear response.
4.1.2. Potential Cause of Death. The day after receiving
EXPAREL at a dosage of 30mg/kg/dose given sc at biweekly
intervals for a total dose of 30mg/kg/dose × 6 injections
= 180mg/kg, one female rabbit was found dead. All other
animals survived the duration of the study even those
receiving a total dose 30mg/kg/dose × 8 injections =
240mg/kg in which the dose exposure was larger higher on
a cumulative basis, and plasma concentrations were present
for a longer period.
The experimental conditions did not allow determina-
tion of the cause of death. It is possible that if this animal
had been monitored constantly, earlier detection of delayed
toxicity may have been possible. Intravascular injection is
unlikely to have been an etiology in our case since the animal
appeared normal on the day of dose administration.
Considering the susceptibility of rabbits to cardiotox-
icity and the fact that, after several repeat injections of
EXPAREL, the compartments, being nearly saturated, may
reach potentially toxic concentrations, led us to speculate
that the lethality may have been caused by hypotension,
respiratorydistress,CVcollapse,and/orsuddenfatalventric-
ular tachycardia and ﬁbrillation with or without hypoxia or
acidosis.
4.1.3. Local Reactions. In recovery rabbits, the local reactions
resolved to some degree, although minimal to mild HEM
(hemorrhage), VMs, NV, and inﬂammation were present in
few animals. The HEM, NV, and inﬂammation (chronic-
active or subacute) seen in the EXPAREL-treated animals
were possibly adverse eﬀects although there was no clear
evidence of a chronic response to EXPAREL consistent
with a harmful response to the immune system. Some of
the local inﬂammatory reactions may be caused by overt
irritation produced by prolonged bupivacaine exposure [50–
53]. There were occasional foci of GCs that surrounded
exogenous basophilic mineralized material presumed to
be DepoFoam or its breakdown products associated with
chronic inﬂammation and mineralization of the exposed tis-
sues or muscles. GCs, common inﬂammatory cells, are fused
Macs (macrophages) partially resulting from the inability
of Macs to phagocytize large particulates. This is a classic
response thatwallsoﬀand surrounds foreignmaterial. These
inﬂammatory defense mechanisms protect the body against
entry of nontoxic foreign body particles. The presence of
VMs appeared to resolve in a dose-dependent manner. The
histiocytic inﬁltrate composed primarily of Macs in the
reactive tissues (walls) likely indicate cellular uptake and
processing of EXPAREL by local Macs.
In dogs, the NOAEL was >30mg/kg/dose. The low-
grade Gi (minimal to moderate) observed with EXPAREL-
dosed groups only decreased in severity, yet persisted in
the recovery animals, and therefore was not considered
reversible. The mineral deposits, commonly surrounded
by GCs, were considered evidence of small amounts of
foreign matter, presumably DepoFoam particles in the loose
connective tissues of the sc space. With the low incidence
and severity, these soft tissues changes are compatible with
a foreign body type reaction following exposure to the tissue
of the test article. The character of the soft tissue reaction
was nonspeciﬁc and did not indicate any special toxic eﬀect
per se. In each species, the highest dose was administered
via application of a concentrated formulation of EXPAREL
(25mg/mL); the formulation of 25mg/mL was intended to
maximize the delivery of EXPAREL to the site of absorption
andwasusedtoincreaseexposureoflocaltissuestorelatively
higher concentrations of both vehicle and drug. Despite the
documented actions of bupivacaine on the musculoskeletal
system, normal function of this system was not aﬀected—
even at both lipid and bupivacaine concentration 1.7 times
higher than the undiluted EXPAREL formulation.
Notably, EXPAREL revealed a predictable sustained
release proﬁle in both species even at high doses. Notably,
species diﬀerence was observed with lower Cmax (↓4f o l d )
and AUC (↓5 fold) for all dose levels for EXPAREL (rabbit
versus dog). The same observation was made for Bsol
with lower Cmax(↓4–9 fold) and AUC (↓4 fold), perhaps
because diﬀerences in tissue binding, vascular uptake, and
hepatic clearance aﬀect drug distribution. After repeat
exposure, the modest accumulation of bupivacaine in rabbit
plasma suggested that the highly concentrated formulation
of EXPAREL was not cleared completely before the next dose
was administered, as would be expected from its prolonged
absorption from the injection sites.12 Journal of Drug Delivery
In contrast, dogs appeared to process bupivacaine sim-
ilarly after the ﬁrst dose and after the last dose; this
ﬁnding is consistent with a lack of toxicity reported in
this experimental model. The gradual input aﬀorded by
EXPAREL allowed enough time for the body to absorb
bupivacaine and processed it without overwhelming the
system even when massive doses were administered.
In summary, we have identiﬁed a species diﬀerence
as reﬂected in the greater incidence of local and systemic
reactions in rabbits compared to dogs. In both species,
EXPAREL was irritating to extravascular soft tissue when
given in large amounts in excess of the clinical dosage. All
microscopic changes at the injection sites were minimal
to mild/moderate. Similar microscopic ﬁndings were not
observed in Bsol or saline control group. In rabbits, the
systemic reactions (tremors/convulsions) were attributed to
an exaggerated response to bupivacaine and were more
frequently observed with Bsol. As a result, a NOAEL was
not identiﬁed in rabbits. The local reactions were expected
consequences of EXPAREL, due to the deposition of foreign
matter in the loose connective tissues of the subcutaneous
space.
4.1.4. Clinical Relevance. The most important considera-
tion in the ﬁndings from these studies is the potential
implications on human risk. While the mechanism(s) that
contributed to convulsions in this study cannot be identiﬁed
with certainty, the toxicological eﬀects of EXPAREL in
rabbits, presumably, are a reﬂection of a low rate, threshold-
sensitive phenomenon that is not operative, and/or antici-
pated in humans under actual condition of exposure (i.e.,
single dose).
In the repeat-dose 28-day studies, the dosing methodol-
ogy was selected to maximize exposure conditions. Under
these conditions, the total cumulative dose of bupivacaine
was regarded as excessive relative to the intended single-dose
administration in the clinic, that is, the dosing regimen far
exceeded the number of doses humans will receive.
In dogs, no eﬀects were noted. In rabbits, convulsions
and one death were noted. The death was recorded in
a female rabbit one day after receiving six injections of
EXPAREL 30mg/kg subcutaneously at biweekly intervals,
which correspond to a total cumulative dose of 30mg/kg
× 6d o s e s= 180mg/kg). Given the fact there was no dose-
related response, the death may have been either incidental
and/orrelatedtoexcessresponsivenesstobupivacaineaction,
that is, the lethality may have been caused by sudden fatal
ventricular tachycardia and ﬁbrillation leading to cardiac
arrest as discussed above.
There is no compelling evidence for this being due to
the cumulative EXPAREL material per se that was injected.
Thereisnoevidencethatthenegativeoutcomeinthisanimal
is related to the speciﬁc formulation of bupivacaine used
(EXPAREL) and/or the vehicle itself, but rather this extreme
ﬁnding was considered to be incidental and/or most likely
attributed to the sensitivity of this particular animal to the
toxic eﬀects of bupivacaine.
The dog ﬁndings appear to be clinically more relevant
than the rabbit, since humans usually do not experience
severe eﬀects unless very high doses of bupivacaine are given.
However, caution must be emphasized since this may not
be always the case. For example, patients with underlying
pathology (e.g., renal failure, acidosis, or cirrhosis) may have
higher sensitivity to the toxic eﬀects of bupivacaine and
structural analogs [54].
It is our opinion that the major factors involved in the
dramatic results seen in the rabbit were due to physiol-
ogical variations and species susceptibility to bupivacaine.
Alteration in regional blood ﬂow, hemodynamic instability,
and a more rapid drug uptake along with a slow egress in
target tissue may render rabbits more susceptible to drug
accumulation and increase the risk of overt toxicity with
prolonged administration of repeated doses.
In summary, the nature and level of the ﬁndings in
rabbits did not present a clinically signiﬁcant safety concern
since EXPAREL will be administered as a single-dose by local
inﬁltration in a clinical setting. The relevance of the rabbit
observations in terms of correlating to humans is limited,
sincethismodelusesexcessivedosagerelativetotheintended
clinical dose. The lack of signiﬁcant toxicology eﬀects in a
second model may provide a higher level of comfort that
EXPAREL does not pose a signiﬁcant health risk especially
after single dose administration. These studies however draw
attention to the potential complications which may occur
whenever bupivacaine in any form is used.
5. Conclusion
Taken together, the data demonstrate that rabbits are more
susceptible to bupivacaine toxicity than dogs. EXPAREL was
well tolerated in dogs during twice weekly administration for
a total of 8 doses over the course of the study (cumulative
NOAEL dose = 240mg/kg). In this species, there was no
indication of local or systemic complications over the course
of the study. In contrast, a NOAEL was not identiﬁed in
rabbits.
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